PMS28 - SECUKINUMAB VERSUS INFLIXIMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.1742
https://www.valueinhealthjournal.com/article/S1098-3015(18)35044-7/fulltext
Section Title :
Section Order :
1109
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35044-7&doi=10.1016/j.jval.2018.09.1742